VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination
VERAXA Biotech AG, formed through a merger with Voyager Acquisition Corp., starts trading on Nasdaq under ticker VRXA, advancing its BiTAC platform for cancer therapies with new financing.
VERAXA Biotech AG (NASDAQ: VRXA) has completed its business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The merger marks a significant milestone for the company, which is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, designed to selectively target cancer cells while sparing healthy tissue.
The transaction, which recently closed, positions VERAXA to advance its lead programs toward clinical development. The company said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support the advancement of its BiTAC-TCE and BiTAC-ADC programs. This capital infusion is critical as VERAXA recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
VERAXA’s BiTAC platform is at the core of its strategy. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Guided by rigorous quality-by-design principles, VERAXA aims to rapidly advance its pipeline into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research.
The business combination with Voyager Acquisition Corp., a special purpose acquisition company focused on revolutionizing the healthcare sector, provides VERAXA with a public listing and access to capital markets. Voyager’s team brings expertise in investing, operations, and medical innovation, which could help scale VERAXA’s operations. For more information about Voyager, visit https://www.voyageracq.com.
The news is important because it signals a new phase for VERAXA, allowing it to leverage public market funding to push its cancer therapies toward clinical trials. With a focus on bispecific T-cell engagers and ADCs, the company addresses a growing demand for targeted cancer treatments that minimize damage to healthy cells. The successful completion of the merger and the concurrent financings provide a financial runway to advance its pipeline, potentially bringing novel therapies to patients.
For regular updates about VERAXA Biotech, visit www.veraxa.com. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.